

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- Claim 1. (Original): A method of preventing and/or treating osteoarthritis in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a calcitonin in free or salt form.
- Claim 2. (Original): A method of inhibiting resorption and/or normalizing turnover of subchondral bone in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a calcitonin in free or salt form.
- Claim 3. (Currently amended): The method according to claims 1-~~or~~2, wherein the therapeutically effective amount of a calcitonin is delivered orally.
- Claim 4. (Currently amended): The method according to claims 1-~~or~~2, wherein the therapeutically effective amount of a calcitonin is delivered orally in a composition comprising the calcitonin and a delivery agent for calcitonin.
- Claim 5. (Currently amended): The method according to claims 1-~~or~~2, wherein the therapeutically effective amount of a calcitonin is delivered orally in a composition comprising the calcitonin which is conjugated to a polymer molecule.
- Claim 6. (Currently amended): The method according to claims 1-~~or~~2, wherein the therapeutically effective amount of a calcitonin is delivered with an effective dosage of an oral pharmaceutical composition comprising calcitonin, at least one pharmaceutically acceptable pH-lowering agent, at least one absorption enhancer, and an enteric coating.
- Claim 7. (Currently amended): The method according to claim 4-~~to~~6, whereas the calcitonin is a salmon calcitonin.
- Claim 8. (Original): The method of claim 4, whereas said pharmaceutical composition comprises a delivery agent selected from the group of 5-CNAC, SNAD and SNAC.
- Claim 9. (Currently amended): The method according to claims 4, whereas said pharmaceutical composition comprises a delivery agent selected from the group consisting of a disodium salt of 5-CNAC, a disodium salt of SNAD and a disodium salt of SNAC.
- Claim 10. (Currently amended): The method according to claims 4, whereas said pharmaceutical composition comprises a delivery agent in micronized form.

Claims 11-13. (Canceled)

Claim ~~15~~14. (Canceled)

Claim ~~16~~15. (Canceled)

Claim ~~17~~16. (Canceled)

Claim ~~18~~17. (Currently amended): A pharmaceutical composition for use in the treatment or/and prevention of osteoarthritis in a patient in need thereof, comprising a calcitonin together with one or more pharmaceutically acceptable diluents or carriers therefore.

Claim ~~19~~18. (Currently amended): A pharmaceutical combination for use in the treatment or/and prevention of osteoarthritis in a patient thereof, comprising:

- a) a first agent which is a calcitonin, and
- b) a co-agent which is a bone resorption inhibitor, bone forming during or pain reducing agent.

Claim ~~20~~19. (Currently amended): A pharmaceutical composition comprising between 0.4 and 2.5 mg of a calcitonin.

Claim ~~21~~20. (Canceled)

Claim ~~22~~21. (Currently amended): A method of preventing or/and treating osteoarthritis in a patient in need thereof comprising administering to said patient a pharmaceutical composition comprising between 0.4 and 2.5 mg of a calcitonin.

Claim ~~23~~22. (Currently amended): A pharmaceutical composition for use in treating or/and preventing osteoarthritis comprising between 0.4 and 2.5 mg of a calcitonin.

Claim ~~24~~23. (Currently amended): The ~~use of claim 21, the~~ method of claim 2221, the ~~composition of claims 18-20 or 23,~~ wherein the calcitonin is salmon calcitonin.